News | June 18, 2012

Data Suggest Convergent Procedure Ablation May Restore Persistent AFib Patients to Normal Sinus Rhythm

Physician presentations at Heart Rhythm 2012 highlight new 12-plus month data, with more than 80 percent in sinus rhythm

June 18, 2012 — Epicardial ablation device maker Contact Inc. announced that new long-term physician data demonstrated promising clinical outcomes for the multidisciplinary convergent procedure in the treatment of persistent atrial fibrillation (AF), with more than 80 percent of patients remaining in sinus rhythm at a minimum of 12 months follow-up. The data was presented by physicians at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions in May. 

During the oral abstract sessions, a presentation by Kenneth C. Civello, M.D., Our Lady of the Lake Medical Center, Baton Rouge, La., highlighted clinical outcomes from 104 consecutive patients treated with the convergent procedure. Of these, 73 percent suffered with persistent or permanent AF. Results demonstrated that 86 percent of patients who reached six months follow-up were in sinus rhythm, with 78 percent in sinus rhythm off anti-arrhythmic drugs (AADs). Of the 40 patients who have reached 12 month follow-up, 81 percent were in sinus rhythm, with 69 percent in sinus rhythm off AADs.

A poster presented by David M. Gilligan, M.D., Levinson Heart Hospital at CJW Medical Center, Richmond, Va., reviewed data from a prospective registry of the first 39 patients to undergo ablation with the convergent procedure at the center, 79 percent of whom suffered with persistent or longstanding persistent AF. At 12 months post procedure, 96 percent of patients were in sinus rhythm with nearly 70 percent in sinus rhythm off AADs.

A poster presented by Keith M. Golden, M.D., St. Vincent Hospital, Indianapolis, Ind. demonstrated positive outcomes on 60 patients undergoing the convergent procedure, considering 88 percent of patients had persistent or longstanding persistent AF. This was a difficult cohort of patients with enlarged left atria, and an average BMI over 35. At an average follow up of 11 months (333 +/- 156 days), 79 percent of patients were in sinus rhythm.  Notably, this continued to hold true for the 14 patients who reached 18 months follow-up, with 79 percent remaining in sinus rhythm, all of whom were also off AADs.

The various posters and presentations reaffirmed the ability of the convergent procedure to achieve consistent single procedure results across hospital sites. The potential advantage of the convergent procedure is that it integrates the best practices of surgeons and electrophysiologists in a single setting, utilizing a minimally invasive, trans-diaphragmatic approach for direct access to the posterior of the left atrium without chest incisions, lung deflation or cardiac dissections. Developed by physicians and enabled by nContact's epicardial ablation technology, it has been shown to be especially appropriate for AF patients with enlarged atria and persistent or long-standing persistent stages of disease.

For more information: www.ncontactinc.com 

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Overlay Init